$9.650
-0.099 (-1.03%)收盘时
PHAR 同业对比
In the context of the broader market, PHAR competes directly with industry leaders such as ZVRA and AVTX. With a market capitalization of $690.09M, it holds a leading position in the sector. When comparing efficiency, PHAR's gross margin of N/A stands against ZVRA's 95.36% and AVTX's N/A. Such benchmarking helps identify whether Pharming Group N.V. is trading at a premium or discount relative to its financial performance.
Pharming Group NV 财务表现
Pharming has a current P/E ratio of 43.02 and a forward P/E of 212.77, indicating potential overvaluation. The company reported a significant earnings surprise of -90% in its last earnings report, with EPS of 0.02 compared to an estimate of 0.20, which raises concerns about its financial health.
Financials
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。